Medicine guide
Refludan
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Lepirudin
- Used in
- Blood, clotting and anaemia
- Made by
- Celgene Europe Ltd.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Anticoagulation in adult patients with heparin-induced thrombocytopenia type II and thromboembolic disease mandating parenteral antithrombotic therapy. The diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Celgene Europe Ltd. |
|---|---|
| Active substance | Lepirudin |
| Used in | Blood, clotting and anaemia |
| Classification | B01AE02 · Blood, clotting and anaemia |
| Authorised on | 1997-03-13 |
| Last updated by the regulator | 2012-07-27 |
| EMA product number | EMEA/H/C/000122 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).